- Home
- SABS vs BIVI Comparison
SABS vs BIVI Comparison
Compare SABS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- BIVI
- Stock Information
- Founded
- SABS 2014
- BIVI 2013
- Country
- SABS United States
- BIVI United States
- Employees
- SABS N/A
- BIVI N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- BIVI Health Care
- Exchange
- SABS Nasdaq
- BIVI Nasdaq
- Market Cap
- SABS 15.8M
- BIVI 14.2M
- IPO Year
- SABS N/A
- BIVI N/A
- Fundamental
- Price
- SABS $2.34
- BIVI $1.97
- Analyst Decision
- SABS Strong Buy
- BIVI
- Analyst Count
- SABS 4
- BIVI 0
- Target Price
- SABS $9.50
- BIVI N/A
- AVG Volume (30 Days)
- SABS 481.4K
- BIVI 234.2K
- Earning Date
- SABS 11-05-2025
- BIVI 11-12-2025
- Dividend Yield
- SABS N/A
- BIVI N/A
- EPS Growth
- SABS N/A
- BIVI N/A
- EPS
- SABS N/A
- BIVI N/A
- Revenue
- SABS $114,698.00
- BIVI N/A
- Revenue This Year
- SABS N/A
- BIVI N/A
- Revenue Next Year
- SABS N/A
- BIVI N/A
- P/E Ratio
- SABS N/A
- BIVI N/A
- Revenue Growth
- SABS N/A
- BIVI N/A
- 52 Week Low
- SABS $1.00
- BIVI $1.42
- 52 Week High
- SABS $6.60
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- SABS 55.11
- BIVI 48.39
- Support Level
- SABS $1.85
- BIVI $1.86
- Resistance Level
- SABS $2.49
- BIVI $2.04
- Average True Range (ATR)
- SABS 0.21
- BIVI 0.12
- MACD
- SABS 0.01
- BIVI 0.07
- Stochastic Oscillator
- SABS 47.00
- BIVI 81.23
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.